Program
sarilumab
Also written as “Sarilumab”, “REGN88” and “sarilumab SAR153191 (REGN88)”.
Its studies are mostly in Arthritis, Rheumatoid · Polymyalgia Rheumatica · Arthritis, Juvenile · Spondylitis, Ankylosing · Coronavirus Infections, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 223 open or running | phase 4since Feb 8, 2018 | Feb 2, 2010 | Mar 1, 2028phase 2 · NCT02991469 |
| Regeneron Pharmaceuticals | 50 open or running | phase 3since Mar 15, 2020 | Nov 10, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Nov 10, 2009.
- Mar 3, 2014Phase 1 study in Arthritis, RheumatoidRegeneron Pharmaceuticals · NCT02097524 · 105 enrolled · United States
- Apr 21, 2014Phase 3 study in Arthritis, RheumatoidSanofi · NCT02121210 · 132 enrolled · United States, Chile, Czechia and more
- Jan 5, 2015Phase 3 study in Arthritis, RheumatoidSanofi · NCT02332590 · 369 enrolled · United States, Chile, Czechia and more
- Feb 12, 2015Phase 3 study in Arthritis, RheumatoidSanofi · NCT02373202 · 91 enrolled · Japan
- Mar 26, 2015Phase 1 study in Arthritis, RheumatoidSanofi · NCT02404558 · 30 enrolled · Japan
- May 16, 2016Phase 2 study in Arthritis, JuvenileSanofi · NCT02776735 · 102 enrolled · United States, Argentina, Canada and more
- Oct 14, 2016Phase 2 study in Arthritis, JuvenileSanofi · NCT02991469 · 51 planned · Argentina, Canada, Finland and more
- Feb 8, 2018Phase 4 study in Arthritis, RheumatoidSanofi · NCT03449758 · 84 enrolled · France
- Jul 17, 2018Phase 3 study in Polymyalgia RheumaticaSanofi · NCT03600818 · 118 enrolled · United States, Argentina, Australia and more
- Mar 15, 2020Phase 3 study in COVID-19Regeneron Pharmaceuticals · NCT04315298 · 1,912 enrolled · United States
- Mar 26, 2020Phase 3 study in Coronavirus InfectionsSanofi · NCT04327388 · 420 enrolled · Argentina, Brazil, Canada and more
- Nov 28, 2023Phase 1 study in Arthritis, RheumatoidSanofi · NCT06159452 · 53 enrolled
- Dec 10, 2025Phase 3 study in Polymyalgia RheumaticaSanofi · NCT07286214 · 300 planned · United States, Austria, Belgium and more
- Jun 22, 2026Phase 2 study in Arthritis, RheumatoidSanofi · NCT07704580 · 140 planned · United States
Ahead
- Mar 1, 2028Primary completion: phase 2 study in Arthritis, JuvenileSanofi · NCT02991469
- Oct 26, 2028Primary completion: phase 2 study in Arthritis, RheumatoidSanofi · NCT07704580
- Jun 4, 2029Primary completion: phase 3 study in Polymyalgia RheumaticaSanofi · NCT07286214
TargetBeta
“A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), ”NCIt, by rule
“Interleukin-6 receptor alpha subunit antagonist”ChEMBL 37, by rule
Other programs on IL6R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tocilizumabrule | Hoffmann-La Roche | phase 4 | 130 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07704580Arthritis, Rheumatoid · United States | 2 | Recruiting | Sanofi | Oct 26, 2028 | 140 |
| NCT07286214Polymyalgia Rheumatica · United States, Austria, Belgium and more | 3 | Recruiting | Sanofi | Jun 4, 2029 | 300 |
| NCT06159452Arthritis, Rheumatoid | 1 | Completed | Sanofi | Dec 21, 2010 | 53 |
| NCT04327388Coronavirus Infections · Argentina, Brazil, Canada and more | 3 | Completed | Sanofi | Jul 31, 2020 | 420 |
| NCT04315298COVID-19 · United States | 3 | Completed | Regeneron Pharmaceuticals | Jul 24, 2020 | 1,912 |
| NCT03600818Polymyalgia Rheumatica · United States, Argentina, Australia and more | 3 | Terminated | Sanofi | May 19, 2021 | 118 |
| NCT03449758Arthritis, Rheumatoid · France | 4 | Completed | Sanofi | Jul 31, 2019 | 84 |
| NCT02991469Arthritis, Juvenile · Argentina, Canada, Finland and more | 2 | Recruiting | Sanofi | Mar 1, 2028 | 51 |
| NCT02776735Arthritis, Juvenile · United States, Argentina, Canada and more | 2 | Completed | Sanofi | Apr 8, 2022 | 102 |
| NCT02404558Arthritis, Rheumatoid · Japan | 1 | Completed | Sanofi | Mar 2016 | 30 |
| NCT02373202Arthritis, Rheumatoid · Japan | 3 | Completed | Sanofi | Nov 2016 | 91 |
| NCT02332590Arthritis, Rheumatoid · United States, Chile, Czechia and more | 3 | Completed | Sanofi | Jan 20, 2016 | 369 |
| NCT02121210Arthritis, Rheumatoid · United States, Chile, Czechia and more | 3 | Completed | Sanofi | May 2015 | 132 |
| NCT02097524Arthritis, Rheumatoid · United States | 1 | Completed | Regeneron Pharmaceuticals | Apr 2015 | 105 |
| NCT01900431Uveitis · United States, Czechia, France and more | 2 | Completed | Sanofi | Jul 2015 | 58 |
| NCT01768572Arthritis, Rheumatoid · United States, Argentina, Belgium and more | 3 | Completed | Sanofi | Oct 2014 | 202 |
| NCT01764997Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Terminated | Sanofi | Jan 2015 | 776 |
| NCT01709578Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Mar 2015 | 546 |
| NCT01328522Arthritis, Rheumatoid · United States | 1 | Completed | Sanofi | Sep 2011 | 32 |
| NCT01217814Arthritis, Rheumatoid · United States, Colombia, Czechia and more | 2 | Terminated | Sanofi | Sep 2011 | 16 |
| NCT01146652Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Dec 31, 2020 | 2,023 |
| NCT01118728Spondylitis, Ankylosing · United States, Australia, Austria and more | 2 | Terminated | Sanofi | Dec 2011 | 223 |
| NCT01061736Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Oct 2013 | 1,675 |
| NCT01061723Spondylitis, Ankylosing · United States, Australia, Austria and more | 2 | Completed | Sanofi | Jun 2011 | 301 |
| NCT01055899Arthritis, Rheumatoid · United States | 1 | Completed | Regeneron Pharmaceuticals | Mar 2009 | 15 |
| NCT01026519Arthritis, Rheumatoid · Russian Federation | 1 | Completed | Regeneron Pharmaceuticals | Mar 2009 | 32 |
| NCT01011959Arthritis, Rheumatoid · United States | 1 | Completed | Regeneron Pharmaceuticals | Aug 2009 | 60 |
How it is read
Names in the registry
- “Sarilumab”, 14 entries
- “REGN88”, 5 entries
- “sarilumab SAR153191 (REGN88)”, 3 entries
- “Sarilumab SAR153191 (REGN88)”, 2 entries
- “SAR153191 (REGN88)”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 18 studies
- Polymyalgia Rheumatica, 2 studies
- Arthritis, Juvenile, 2 studies
- Spondylitis, Ankylosing, 2 studies
- Coronavirus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.